Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex

Congenital subependymal giant cell astrocytomas in patients with tuberous sclerosis complex

(2014) Katarzyna Kotulska et al.   CHILDS NERVOUS SYSTEM

Mammalian Target of Rapamycin Inhibitors for Intractable Epilepsy and Subependymal Giant Cell Astrocytomas in Tuberous Sclerosis Complex

(2014) Michael Cardamone et al.   JOURNAL OF PEDIATRICS

Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study

(2014) David Neal Franz et al.   LANCET ONCOLOGY

Strategies for the management of adverse events associated with mTOR inhibitors

(2014) Bruce Kaplan et al.   Transplantation Reviews

Everolimus treatment of refractory epilepsy in tuberous sclerosis complex

(2013) Darcy A. Krueger et al.   ANNALS OF NEUROLOGY

Long-term effect of everolimus on epilepsy and growth in children under 3 years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex

(2013) Katarzyna Kotulska et al.   EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY

A Novel Topical Rapamycin Cream for the Treatment of Facial Angiofibromas in Tuberous Sclerosis Complex

(2013) James W. Wheless et al.   JOURNAL OF CHILD NEUROLOGY

Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial

(2013) John J Bissler et al.   LANCET

mTOR kinase structure, mechanism and regulation

(2013) Haijuan Yang et al.   NATURE

Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma

(2013) D. A. Krueger et al.   NEUROLOGY

Tuberous Sclerosis Complex Surveillance and Management: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference

(2013) Darcy A. Krueger et al.   PEDIATRIC NEUROLOGY

Tuberous Sclerosis Complex Diagnostic Criteria Update: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference

(2013) Hope Northrup et al.   PEDIATRIC NEUROLOGY

Sirolimus treatment of severe PTEN hamartoma tumor syndrome: case report and in vitro studies

(2013) Gordian L. Schmid et al.   PEDIATRIC RESEARCH

Topical Rapamycin Therapy to Alleviate the Cutaneous Manifestations of Tuberous Sclerosis Complex

(2013) Mary Kay Koenig et al.   Drugs in research & development

Phase I/IIa trial of the mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) administered orally in patients with refractory or advanced malignancies and sarcoma

(2012) M. M. Mita et al.   ANNALS OF ONCOLOGY

Outcomes of resecting subependymal giant cell astrocytoma (SEGA) among patients with SEGA-related tuberous sclerosis complex: a national claims database analysis

(2012) Peter Sun et al.   CURRENT MEDICAL RESEARCH AND OPINION

Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial

(2012) David Neal Franz et al.   LANCET

Autophagy

(2011) Jane Yu et al.   Autophagy

Treatment of facial angiofibromas with topical application of oral rapamycin solution (1 mg mL−1) in two patients with tuberous sclerosis

(2011) M.M. Mutizwa et al.   BRITISH JOURNAL OF DERMATOLOGY

Sirolimus Therapy for Angiomyolipoma in Tuberous Sclerosis and Sporadic Lymphangioleiomyomatosis: A Phase 2 Trial

(2011) D. M. Davies et al.   CLINICAL CANCER RESEARCH

Functional assessment of variants in the TSC1 and TSC2 genes identified in individuals with Tuberous Sclerosis Complex

(2011) Marianne Hoogeveen-Westerveld et al.   HUMAN MUTATION

Sustained clinical effectiveness and favorable safety profile of topical sirolimus for tuberous sclerosis - associated facial angiofibroma

(2011) R. Salido et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Efficacy and Safety of Sirolimus in Lymphangioleiomyomatosis

(2011) Francis X. McCormack et al.   NEW ENGLAND JOURNAL OF MEDICINE

Everolimus for Advanced Pancreatic Neuroendocrine Tumors

(2011) James C. Yao et al.   NEW ENGLAND JOURNAL OF MEDICINE

Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

(2011) José Baselga et al.   NEW ENGLAND JOURNAL OF MEDICINE

Oral rapamycin in the treatment of patients with hamartoma syndromes and PTEN mutation

(2011) Ionela Iacobas et al.   PEDIATRIC BLOOD & CANCER

Sirolimus for the treatment of complicated vascular anomalies in children

(2011) Adrienne M. Hammill et al.   PEDIATRIC BLOOD & CANCER

Multicenter Phase 2 Trial of Sirolimus for Tuberous Sclerosis: Kidney Angiomyolipomas and Other Tumors Regress and VEGF- D Levels Decrease

(2011) Sandra L. Dabora et al.   PLoS One

Common toxicities of mammalian target of rapamycin inhibitors

(2011) Scott A. Soefje et al.   Targeted Oncology

Everolimus Plus Reduced-Exposure CsA versus Mycophenolic Acid Plus Standard-Exposure CsA in Renal-Transplant Recipients

(2010) H. Tedesco Silva Jr. et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Confirmation study of PTEN mutations among individuals with autism or developmental delays/mental retardation and macrocephaly

(2010) Kim L. McBride et al.   Autism Research

Phase 3 trial of everolimus for metastatic renal cell carcinoma

(2010) Robert J. Motzer et al.   CANCER

Immunosuppressant Neurotoxicity in Rat Brain Models: Oxidative Stress and Cellular Metabolism

(2010) Jelena Klawitter et al.   CHEMICAL RESEARCH IN TOXICOLOGY

Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous Sclerosis

(2010) Darcy A. Krueger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Management of subependymal giant cell tumors in tuberous sclerosis complex: the neurosurgeon’s perspective

(2010) Berhouma Moncef   World Journal of Pediatrics

A complex interplay between Akt, TSC2 and the two mTOR complexes: Figure 1

(2009) Jingxiang Huang et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

Pharmacological Inhibition of mTORC1 Suppresses Anatomical, Cellular, and Behavioral Abnormalities in Neural-Specific Pten Knock-Out Mice

(2009) J. Zhou et al.   JOURNAL OF NEUROSCIENCE

Rapamycin (sirolimus) in tuberous sclerosis associated pediatric central nervous system tumors

(2009) Catherine Lam et al.   PEDIATRIC BLOOD & CANCER

The TSC1–TSC2 complex: a molecular switchboard controlling cell growth

(2008) Jingxiang Huang et al.   BIOCHEMICAL JOURNAL

Chemoprevention and Treatment of Experimental Cowden's Disease by mTOR Inhibition with Rapamycin

(2008) C. H. Squarize et al.   CANCER RESEARCH

Missense mutations to the TSC1 gene cause tuberous sclerosis complex

(2008) Mark Nellist et al.   EUROPEAN JOURNAL OF HUMAN GENETICS

Regression of Subependymal Giant Cell Astrocytoma With Rapamycin in Tuberous Sclerosis Complex

(2008) Mary Kay Koenig et al.   JOURNAL OF CHILD NEUROLOGY

Phase I Trial of the Novel Mammalian Target of Rapamycin Inhibitor Deforolimus (AP23573; MK-8669) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients With Advanced Malignancies

(2008) Monica M. Mita et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With Advanced Solid Tumors

(2008) Anne O'Donnell et al.   JOURNAL OF CLINICAL ONCOLOGY

Subependymal giant cell astrocytoma (SEGA): Is it an astrocytoma? Morphological, immunohistochemical and ultrastructural study

(2008) Anna M. Buccoliero et al.   NEUROPATHOLOGY

Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or Lymphangioleiomyomatosis

(2008) John J. Bissler et al.   NEW ENGLAND JOURNAL OF MEDICINE